Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P98194

UPID:
AT2C1_HUMAN

ALTERNATIVE NAMES:
ATP-dependent Ca(2+) pump PMR1; Ca(2+)/Mn(2+)-ATPase 2C1; Secretory pathway Ca(2+)-transporting ATPase type 1

ALTERNATIVE UPACC:
P98194; B2RAT7; B4DSW3; B7Z3X9; G3XAH8; G8JLN9; O76005; Q86V72; Q86V73; Q8N6V1; Q8NCJ7

BACKGROUND:
The protein Calcium-transporting ATPase type 2C member 1, with aliases such as Ca(2+)/Mn(2+)-ATPase 2C1, is integral for the ATP-driven supply of Ca(2+) and Mn(2+) ions to the Golgi apparatus. These ions are vital cofactors in the secretory pathway for protein processing and trafficking. The protein's function includes a significant impact on Golgi and post-Golgi protein sorting, influencing both the structural morphology of cisternae and the integrity of the epidermis.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in skin health and disease, particularly in Hailey-Hailey disease, the study of Calcium-transporting ATPase type 2C member 1 offers promising avenues for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.